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Abstract
Background: Lateral lymph node (LLN) metastasis is a major cause of local recurrence of advanced rectal cancer.
Although there is much controversy between Western and Eastern countries on whether lateral pelvic lymph node
dissection (LLND) or neoadjuvant chemo-radiation (nCRT) is preferable for the treatment of LLN metastases, existing
retrospective cohorts mainly focus on all middle/low advanced rectal cancer patients, not the specific individuals
with suspicion of LLN metastases. The aim of this trial is to assess the efficacy and safety of LLND for rectal cancer
patients with suspicion of LLN metastases.
Methods: This prospective, multicenter, randomized controlled, single-blinded, phase III trial is designed to enroll
512 eligible patients with advanced rectal cancer and preoperative enlarged lateral lymph nodes. The population
will be randomly assigned into the solely total mesorectal excision (TME) group or the TME + LLND group after
eligible selection. The primary outcomes are to be 3-year local recurrence rate and 3-year disease-free survival, and
the secondary outcomes include 3-year overall survival, 1-year sexual and urinary function, and perioperative
outcomes.
Discussion: This is the first randomized trial to investigate the efficacy and safety of LLND for advanced low rectal
cancer patients with suspicion of LLN metastases; the result is expected to provide new evidence for the treatment
of LLN where there is suspicion of metastases in advanced rectal cancer patients.
Trial registration: This trial was registered at ClinicalTrials.gov (identifier NCT02614157) Registered on 24 November
2015.
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Background
Rectal cancer is the third most common cancer and the
fourth leading cause of cancer-related deaths worldwide
[1]. Local recurrence of middle/low rectal cancer is not
only a poor prognostic factor but also a threat of a ter-
rible quality of life. Although universal usage of neoadju-
vant chemo-radiation (nCRT) and total mesorectal
excision (TME) have decreased local recurrence rates to
5–10%, the ratio of local recurrence has occupied almost
30% of total metastases and recurrence incidences,
which heavily limits the therapeutic effect for advanced
rectal cancer [2]. Increasing evidence has demonstrated
that lateral pelvic lymph node (LLN) metastasis is a
major cause of local recurrence of advanced rectal can-
cer [3]. At the time of diagnosis, 10–25% of patients
with advanced rectal cancer have synchronous LLN me-
tastases, which consequently lead to local recurrence
and poor overall survival [4, 5].
Regarding the treatment strategy for LLN metastases,
there is much controversy between Western and Eastern
countries on whether lateral pelvic lymph node dissec-
tion (LLND) [6–10] or nCRT [11, 12] is the best treat-
ment option. Eastern countries, especially Japan, favor
LLND following TME for the following reasons: (1) the
incidence of LLN metastases reaches as high as 10–25%,
and 27% of rectal cancer patients who undergo TME
solely (without LLND) would develop local recurrence
[13–16], (2) the efficacy of LLND equals that of resec-
tion of local lymph node metastases. A large cohort of
11,567 cases from Japan demonstrates that resection of
metastatic iliac lymph nodes does not show any differ-
ences between TME in patients with clinical stage
TxN2aM0, and resection of obturator and external iliac
lymph nodes favors that of liver metastasis [11], and (3)
Japanese guidelines for the treatment of colorectal can-
cer in 2014 still recommend that patients with stages II/
III rectal cancer below the peritoneal reflection undergo
regular TME + LLND [17].
On the contrary, Western countries favor nCRT and
TME for LLN metastases, holding that: (1) the rate of
LLN metastases is relatively low, and LLN metastases
are regarded as systemic metastases, (2) LLND involves
longer operative time, higher postoperative complica-
tions, and results in a poorer quality of life. Therefore,
American NCCN and European ESMO guidelines rec-
ommend single TME for rectal cancer but, if necessary,
LLDN is added when LLN indeed show evidence of
metastases.
Despite this, existing retrospective cohorts mainly
focus on all middle/low advanced rectal cancer patients,
not the specific individuals with suspicion of LLN me-
tastases. And those results indicate almost no differences
in local recurrence and overall survival, except for longer
operation time, more blood loss, and more perioperative
complications for LLND [7–9, 18]. A Korean report en-
rolled 900 advanced rectal cancer patients with pre-
operative swollen LLNs, which showed that the
recurrence rate was associated with the diameter of the
LLNs [16]. However, there is no strict prospective ran-
domized controlled study on the comparison of TME +
LLND and TME for low rectal cancer with suspicion of
LLN metastases after nCRT. Thus, the objective of this
study is to assess the efficacy and safety of LLND for
low rectal cancer patients with suspicion of LLN metas-
tases (TME + LLND versus TME). Furthermore, the risk
factors (such as radiologic factors, pathologic factors,
and serum protein) to predict local recurrence and over-
all survival will be further investigated.
Methods
Study design
This is a prospective, multicenter, randomized con-
trolled, single-blinded, phase III trial in which patients
will be randomly assigned into two parallel comparison
groups (the TME + LLND group and the TME group).
The flow diagram of this trial is shown in Fig. 1. Our
trial began in May 2016 in the West China Hospital of
Sichuan University and is expected to end in 2022.
Ethics
This trial protocol has been approved by the Ethics Com-
mittee of West China Hospital of Sichuan University on
13 May 2016 with protocol number 89, and is registered
at ClinicalTrials.gov (identifier NCT02614157). Written
informed consent will be obtained from every patient.
Study population
The inclusion and exclusion criteria of our trial are
shown in Table 1. All eligible patients will strictly com-
ply with the criteria.
Randomization and blinding
All eligible participants meeting the inclusion criteria will
be randomly allocated into either the TME+ LLND group
or the TME group. Based on one previous study,
randomization is performed using a computer-generated,
blocked randomization sequence with a block size of 4 at
a 1:1 ratio [19]. The patients will be informed about the
treatment details upon admission the day before surgery.
Owing to the specificity and ethics, this trial allows the
participants, the surgeon, and the investigators to be
aware of the whole assignment.
Intervention
After randomization, all participants will firstly receive a
cycle of 5-fluorouracil with oxaliplatin therapy (FOLFOX)
or capecitabine (Xeloda) with oxaliplatin therapy
(XELOX). Subsequently, radiotherapy with 50.4 Gy is
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administered in 28 separate doses. Next, three cycles
of FOLFOX or XELOX will be continued. About 3 to
4 weeks later, patients allocated to the TME group
will undergo standard TME surgery solely, while pa-
tients allocated to the TME + LLND group will
undergo standard TME surgery plus LLND. The ex-
tent of LLND includes bilateral LLND (lymph node
groups 263P, 263D, and 283). If the short-axis diam-
eter of the external iliac or common iliac lymph
nodes is beyond 6 mm, lymph node groups 293, 273,
and 280 will be dissected. Unilateral LLND will be done
only when the center of the rectal tumor is limited to a
single side (not beyond the midline) and the contralateral
lymph nodes are not enlarged. Adjuvant chemotherapy,
consistent with the preoperative scheme in every patient,
will be continued until reaching eight cycles.
Outcomes
The primary outcomes of this trial are the 3-year local
recurrence rate and 3-year disease-free survival (DFS).
The local recurrence is defined as recurrent disease in
the pelvis or at the incision and DFS is defined as the
time of surgery to the recurrence or end of follow-up. It
is diagnosed using the following methods: (1) histo-
logical confirmation by biopsy, (2) confirmation by posi-
tron emission tomography-computed tomography (PET-
CT), (3) CT/magnetic resonance imaging (MRI) shows
that there is a mass in the pelvis which is growing with/
without symptoms.
The secondary outcomes include 3-year overall survival
(OS) and disease-free survival (DFS) at 3 years post surgery,
sexual and urinary function at 1 year post surgery, and peri-
operative outcomes. OS is defined as the time of surgery to
the date of death from any cause or the date of follow-up.
Sexual function for men and women is assessed by using
the International Index of Erectile Function-5 scoring sys-
tem (IIEF-5) and the Female Sexual Function Index (FSFI),
respectively [20, 21]. Urinary function is assessed by using
the International Prostate Symptom Score (IPSS) [22]. Peri-
operative outcomes include operation time, intraoperative
blood loss, intraoperative transfusion, incision length, intra-
operative complications, time to first flatus, time to liquid
diet intake, postoperative hospitalization days, postoperative
complications, and mortality.
Fig. 1 Example template of recommended content for the schedule of enrollment, interventions, and assessments
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Follow-up
All participants will be followed up regularly as per
schedule (Table 2). Biopsy or PET-CT would be done
when it is necessary to diagnose recurrence.
Data collection and management
We have invited more than 10 large medical centers,
which have developed experienced LLND surgery in
China, to participate in this trial. We have made univer-
sal standards including inclusion and exclusion criteria,
nCRT, and TME + LLND standard for all units. In order
to obtain good-quality monitoring, we have hired a pro-
fessional clinical research company to organize and
manage the work of all participant units. A Case Report
Form is made for each participant to record their data.
Dropping out
When this trial begins, a participant can drop out of this
trial even if written informed consent has been signed if:
(1) the participant decides to refuse for any reason, (2) un-
acceptable adverse events are experienced, (3) an investi-
gator withdraws the participant for that participant’s
benefit, (4) a participant receives other treatment, such as
biological immune therapy, which is not approved in this
trial, (5) a participant becomes pregnant in the process of
this trial, and (6) the compliance of the participant is poor.
Safety and adverse effect
All adverse events must be carefully recorded and re-
ported, including nCRT complications and perioperative
complications. All severe adverse events in this trial
should be reported every 6 months and adverse events
which are life-threatening should be recorded and re-
ported within 24 h.
Table 1 The inclusion and exclusion criteria
Inclusion criteria:
•Age (years): 18–75
•Histologically confirmed rectal cancer
•Clinical stage: cTxN1-2M0 or cT3-4N0M0
•Suspicion of LLN metastasis: short-axis diameter of lateral lymph nodes
(LLN) >5 mm; short diameter of common iliac or external iliac lymph
nodes >6 mm [16, 24, 25]
•No extramesorectal lymph node swelling (short-axis diameter <10 mm)
•No invasion of other organs
•Performance Status (PS): 0, 1
•No past history of chemotherapy, pelvic surgery, or radiation
•Written informed consent operative criteria:
•Mesorectal excision is performed
•Operative findings:
Main lesion of the tumor is located at the rectum
Lower tumor margin is below the peritoneal reflection
Stage R0 after resection
Exclusion criteria:




•Patients with psychological disorder
•Steroid administration
•Cardiac infarction within previous 6 months
•Severe pulmonary emphysema and/or pulmonary fibrosis
•Physician’s decision to exclude
•Patients with confirmed LLN metastasis: short-axis diameter of LLN >10
mm and a lymph node with an irregular edge, heterogeneous signal, or
obvious enlargement and after nCRT has been completed, lymph node
enlarges more than 30%
•Emergency surgery
•Patients with coagulopathies
Table 2 Trial schedule
Measures M1 M3 M6 M9 M12 M18 M24 M30 M36
Physical examination × × × × × × × × ×
Blood test × × × × × × × × ×
CEA × × × × × × × × ×
CA 19-9 × × × × × × × × ×
CT of chest × × × × × ×
CT/MRI of abdomen and pelvis × × × × × ×
Colonoscopy × × × × × ×
IIEF-5 × × × × ×
FSFI × × × × ×
IPSS × × × × ×
CA cancer antigen, CEA carcinoembryonic antigen, CT computed tomography, FSFI Female Sexual Function Index, IIEF International Index of Erectile Function, IPSS
International Prostate Symptom Score, M month, MRI magnetic resonance imaging
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Sample size and statistical analysis
Our trial aims to demonstrate that LLND could decrease
the 3-year local recurrence rate of low rectal cancer
patients with suspicion of LLN metastases. Based on
previous studies, we assume that the 3-year local recur-
rence rate for patients with suspicion of LLN metastases
who do not undergo LLND is 15% [13–16], and LLND
is expected to show a reduction of 7 percentage points.
G*Power 3.1 is used to calculate the sample size. A
statistical power of 0.80 and a significance level of 0.05
are chosen, and we assume that there will be a 10%
dropout rate. Therefore, 512 patients are needed in this
specific trial (256 patients in each group).
All participants in this trial will be analyzed using the
intention-to-treat analysis. The chi-square test and
Student’ t test will be used to compare categorical data
and continuous data for the two groups, respectively.
The 3-year local recurrence rate, the primary endpoint
of this trial, will be analyzed using the Kaplan-Meier
method, as well as OS and DFS. In addition, based on
different characteristics (such as age, sex, tumor stages,
etc.), which can identify the influence of competing risk
factors, the Cox proportional hazards (PH) regression
model will be tested if Schoenfeld Residuals Analysis
confirms PH assumption validation. Otherwise, an alter-
native extended Cox PH model will be used. SPSS 21.0
(SPSS Inc., Chicago, IL, USA) will be used for all statistical
analyses, and a P value < 0.05 is considered significant.
Discussion
Currently, the hot issue of the treatment of LLN in ad-
vanced rectal cancer patients is still being debated in dif-
ferent regions. Eastern countries, especially Japan, favor
LLND following TME; however, Western countries be-
lieve that nCRT and TME is recommended, and LLDN
is added only when a LLN is preoperatively diagnosed as
metastatic. Actually, preoperatively enlarged LLNs are
not common and only a small proportion of LLDs with
a maximum short-axis diameter ≥10 mm, or with a spi-
culated or indistinct border, or a mottled heterogenic
pattern are diagnosed as metastatic [23]. The remaining
large proportion of LLNs are underdiagnosed as being
metastatic and often confuse surgeons’ treatment strat-
egy. Thus, our trial pays particular attention to this
stratification of suspicious LLNs, assessing the efficacy
and safety of the LLND in advanced rectal cancer
patients.
Another issue we have considered in our trial is the
randomization time. In our trial, we randomly allocated
participants before nCRT rather than after nCRT.
Because LLN metastases are commonly diagnosed be-
fore nCRT by their features on pelvic MRI or CT and
when chemo-radiation has achieved its effect, the
treatment-sensitive regions of any enlarged LLNs will
have decreased in size which may confuse the
randomization if allocation is performed after nCRT.
This trial is the first randomized controlled trial to investi-
gate the role of LLND in reducing local recurrence rates for
low advanced rectal cancer patients with suspicion of LLN
metastases. If the efficacy of LLND is verified, which reduces
the local recurrence rate from 15% to 8%, LLND can be
recommended as a new standard strategy for low advanced
rectal cancer patients with suspicion of LLN metastases.
Trial status
This trial was initiated in May 2016 and is currently
enrolling patients.
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